MEDFORD, N.Y. , Sept. 12, 2016 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that John Sperzel , Chembio's chief executive officer, will make a corporate presentation at the Rodman & Renshaw
MEDFORD, N.Y., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that John Sperzel, Chembio's chief executive officer, will make a corporate presentation at the Rodman & Renshaw
MEDFORD, N.Y., Aug. 25, 2016 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has been awarded a contract for up to $13.2 million in total funding from the U.S.
MEDFORD, N.Y., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases ("Chembio" or the "Company"), announced today the completion of an underwritten public offering of 2,300,000 shares of Chembio's common
MEDFORD, N.Y., July 29, 2016 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases ("Chembio" or the "Company"), today announced the upsizing and pricing of its previously announced underwritten public offering of
MEDFORD, N.Y., July 25, 2016 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI) (the "Company") today announced that it has commenced an underwritten public offering of $10.0 million of common shares (the "Offering"). In addition, the Company intends to grant the underwriters a 30-day
Print Page